This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Centene (CNC) to Sell Magellan Arm, To Use Proceeds for Buybacks
by Zacks Equity Research
Centene (CNC) strikes a deal with Evolent to divest Magellan Specialty Health, a Magellan Health arm, to deepen focus on solidifying its core Managed Care business.
InMed (INM) Gets Grant to Begin Neurodegenerative Diseases Program
by Zacks Equity Research
InMed Pharmaceuticals (INM) surges on receiving research grant funding from the Natural Sciences and Engineering Research Council of Canada (NSERC) to investigate its cannabinoid drug candidates.
Are Medical Stocks Lagging Kiniksa Pharmaceuticals (KNSA) This Year?
by Zacks Equity Research
Here is how Kiniksa Pharmaceuticals, Ltd. (KNSA) and Assertio (ASRT) have performed compared to their sector so far this year.
Assertio (ASRT) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Assertio (ASRT) delivered earnings and revenue surprises of 14.29% and 9.20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
ASRT vs. ZTS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ASRT vs. ZTS: Which Stock Is the Better Value Option?
Zoetis' (ZTS) Lags Q3 Earnings Estimates, Lowers 2022 Guidance
by Zacks Equity Research
Zoetis' (ZTS) earnings miss estimates in third-quarter 2022. Revenues, though up, also miss estimates due to the supply constraints in the international market. Zoetis lowers its financial guidance.
United Therapeutics (UTHR) Q3 Earnings & Sales Beat Estimates
by Zacks Equity Research
United Therapeutics' (UTHR) third-quarter earnings and sales beat estimates. Higher sales of Tyvaso drive the top line in the quarter.
Assertio (ASRT) Stock Moves -1.12%: What You Should Know
by Zacks Equity Research
Assertio (ASRT) closed the most recent trading day at $2.65, moving -1.12% from the previous trading session.
Are Investors Undervaluing Assertio (ASRT) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Assertio (ASRT) Stock Moves -0.41%: What You Should Know
by Zacks Equity Research
In the latest trading session, Assertio (ASRT) closed at $2.45, marking a -0.41% move from the previous day.
Is Assertio (ASRT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Assertio (ASRT) and Pliant Therapeutics, Inc. (PLRX) have performed compared to their sector so far this year.
Assertio (ASRT) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Assertio Holdings' (ASRT) third-quarter performance is likely to reflect the sales performance of its marketed drugs and cost savings from the company's restructuring plans.
ASRT or UTHR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ASRT vs. UTHR: Which Stock Is the Better Value Option?
Assertio (ASRT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Assertio (ASRT) closed at $2.21, marking a +1.38% move from the previous day.
Select Medical (SEM) Plans 3rd Hospital in Central Pennsylvania
by Zacks Equity Research
Select Medical (SEM) joins forces with UPMC to open its third inpatient rehabilitation hospital in Central Pennsylvania to better address the region's post-acute care needs.
Here is What to Know Beyond Why Assertio Holdings, Inc. (ASRT) is a Trending Stock
by Zacks Equity Research
Zacks.com users have recently been watching Assertio (ASRT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Assertio (ASRT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Assertio (ASRT) closed the most recent trading day at $2.31, moving +1.76% from the previous trading session.
ASRT vs. STVN: Which Stock Is the Better Value Option?
by Zacks Equity Research
ASRT vs. STVN: Which Stock Is the Better Value Option?
Why Should You Retain Cigna (CI) in Your Portfolio Now?
by Zacks Equity Research
Cigna (CI) is aided by powerful segmental performances, solid demand for its Medicare plans, divestitures and solid cash-generating abilities.
Is Assertio (ASRT) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Assertio (ASRT) and Humana (HUM) have performed compared to their sector so far this year.
Assertio (ASRT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Assertio (ASRT) closed at $2.15 in the latest trading session, marking a +0.94% move from the prior day.
Is Trending Stock Assertio Holdings, Inc. (ASRT) a Buy Now?
by Zacks Equity Research
Assertio (ASRT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Pacira's (PCRX) Label Expansion Study on Exparel Meets Goal
by Zacks Equity Research
Pacira's (PCRX) phase III study evaluating its marketed drug, Exparel, as a single-dose sciatic nerve block in the popliteal fossa for bunionectomy meets primary and secondary endpoints.
Down 18.3% in 4 Weeks, Here's Why Assertio (ASRT) Looks Ripe for a Turnaround
by Zacks Equity Research
Assertio (ASRT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Assertio (ASRT) Flat As Market Sinks: What You Should Know
by Zacks Equity Research
Assertio (ASRT) closed at $2.24 in the latest trading session, marking no change from the prior day.